After an intensive three-year hunt through the genome, medical researchers have pinpointed mutations that leads to drug resistance and relapse in the most common type of childhood cancer—the first time anyone has linked the disease's reemergence to specific genetic anomalies.
The discovery, co-lead by William L. Carroll, MD, director of NYU Langone Medical Center's Cancer Institute, is reported in a study published online February 3, 2013, in Nature Genetics.
"There has been no progress in curing children who relapse, in spite of giving them very high doses of chemotherapy and bone marrow transplants," said Dr. Carroll.
The discovery suggests how scientists may be able to thwart a dangerous form of acute lymphoblastic leukemia, a rapidly progressing blood-borne cancer that strikes about 6,000 people in the United States every year and accounts for more than one in four pediatric cancers. Eventually, such information could help doctors detect the early emergence of chemotherapy-resistant leukemia cells in patients and switch to a different treatment strategy before the disease can fully reassert itself.
In acute lymphoblastic leukemia, abbreviated ALL, the body's bone marrow produces an abnormally large number of lymphocytes, or white blood cells. Improved treatments have increased the overall cure rate to roughly 80 percent. But Dr. Carroll says the prognosis is especially dire for some 20 percent of patients who relapse.
Medical researchers have suspected that the reemergence of disease could be due to drug resistance, but previous efforts had not uncovered any definitive pathway. For the new study, led by Dr. Carroll and graduate student Julia Meyer, researchers at five U.S. institutions spent three years analyzing multiple bone marrow samples from pediatric ALL patients for more clues to the disease's progression.
With the help of the Children's Oncology Group, a multi-institutional clinical trials consortium supported by the National Cancer Institute, the researchers analyzed the entire transcriptome—or the full sequence of RNA —from 10 children with pediatric B lymphoblastic leukemia, the most common subtype of ALL. RNA is an essential intermediary in the cellular process that uses DNA blueprints to assemble specific proteins, thus a leukemia transcriptome gives researchers a view of all active genes within the cancerous cells.
For each patient, the team pieced together a complete sequence of RNA extracted from the bone marrow at three time points: at diagnosis, during remission, and upon relapse some months or years later. All told, the project required the researchers to sequence, or spell out, 100 billion letters of RNA. By comparing the before and after sequences, the team found that each patient had acquired between one and six mutations that changed the genetic code over the course of the disease. In some cases researchers were able to detect these mutations in a very small subset (0.01 percent) of the tissue samples at diagnosis so that these cells likely expanded because their drug resistant properties provided the leukemia cells with a survival advantage.
In all, the team documented 20 relapse-specific mutations—none of which had previously been implicated in ALL recurrences. Intriguingly, two patients harbored a mutation in the same gene, NT5C2, which encodes a protein that normally regulates some building blocks used to construct DNA but also can degrade an important class of drugs called purine analogues used in ALL therapy.
When the researchers fully sequenced the NT5C2 gene in 61 other cases in which pediatric ALL patients had relapsed, they found five more mutations that altered the gene's coding region. Further experiments suggested that these NT5C2 mutations all increased the protein's enzymatic activity, making the cancer cells more resistant to a chemotherapy treatment designed to force the cells to kill themselves. All seven patients with NT5C2 mutations relapsed within three years of the initial diagnosis—an early, particularly hard-to-treat re-emergence likely mediated by the drug resistance.
Armed with the new knowledge, Dr. Carroll says doctors may be better equipped to identify patients likely to relapse. "We plan to test the feasibility of screening patients during therapy using sophisticated sequencing technology to pick up low-level mutations in NT5C2 and other genes indicating that a mutant clone is growing," he says. His team is researching whether that advance warning could allow doctors to administer separate drugs to beat back the cancer cells, and is also working on a strategy to directly inhibit the mutant enzyme.
The study co-authors include Julia A. Meyer, Jinhua Wang, Laura A. Hogan, Smita Dandekar, Zuojian Tang, Jiri Zavadil, Timothy Cardozo, Elizabeth Raetz, and Debra J. Morrison at NYU Langone Medical Center; Jun J. Yang and William E. Evans at St. Jude Children's Research Hospital; Jay P. Patel and Ross L. Levine at Memorial Sloan-Kettering Cancer Center; Paul Zumbo, Sheng Li, and Christopher E. Mason at Weill Cornell Medical College of Cornell University; and Stephen. P. Hunger at the University of Colorado School of Medicine and Children's Hospital Colorado.
The research was supported by the National Institutes of Health and National Cancer Institute, with additional support from the American Society of Hematology and St. Baldrick's Foundation.
About the NYU Cancer Institute:
The research mission of the NYU Cancer Institute is to discover the origins of cancer and use that knowledge to eradicate the personal and societal burden of cancer in our community and around the world. Fifteen research programs are organized as scientific research programs, focused on the fundamental biology of cancer in general, and as disease-specific research programs centered on individual types of cancer, such as breast or lung cancer. Translational research, a hallmark of the institute, is finding new ways to integrate the extraordinary growth and understanding made in basic research with the ever-growing need for the development of new therapies and approaches in the clinic to a variety of cancers that have remained difficult to treat. To help translate discovery into clinical practice, the NYU Cancer Institute has embarked on five programs that integrate efforts in laboratory investigation and clinical care: cancer targets and novel therapeutics, community and environment, integrative health, molecular oncology/cancer genomics, and immune- and stem-cell-based therapies.
About NYU Langone Medical Center:
NYU Langone Medical Center, a world-class, patient-centered, integrated, academic medical center, is one of the nation's premier centers for excellence in clinical care, biomedical research and medical education. Located in the heart of Manhattan, NYU Langone is composed of four hospitals – Tisch Hospital, its flagship acute care facility; the Hospital for Joint Diseases, one of only five hospitals in the nation dedicated to orthopaedics and rheumatology; Hassenfeld Pediatric Center, a comprehensive pediatric hospital supporting a full array of children's health services; and the Rusk Institute of Rehabilitation Medicine, the world's first university-affiliated facility devoted entirely to rehabilitation medicine– plus NYU School of Medicine, which since 1841 has trained thousands of physicians and scientists who have helped to shape the course of medical history. The medical center's tri-fold mission to serve, teach and discover is achieved 365 days a year through the seamless integration of a culture devoted to excellence in patient care, education and research. For more information, go to www.NYULMC.org.
Christopher Rucas | EurekAlert!
Single atom alloy platinum-copper catalysts cut costs, boost green technology
09.10.2015 | Tufts University
Controllable protein gates deliver on-demand permeability in artificial nanovesicles
09.10.2015 | Universität Basel
Magnete sind aus dem Physikunterricht gut bekannt, im Fach Chemie werden sie dagegen nicht behandelt. Und doch ist es ein chemisches Verfahren, mit dem es Forschern am Karlsruher Institut für Technologie (KIT) gelungen ist, die magnetischen Eigenschaften von Ferromagneten zu steuern. Während physikalische Verfahren zwar die Ausrichtung des Magnetfeldes beeinflussen können, steuert hier das chemische Verfahren den Magnetismus des Materials selbst. Das genutzte Prinzip ist dabei dem Konzept des Lithium-Ionen-Akkus ähnlich. (DOI: 10.002/adma-201305932)
Über physikalische Effekte gibt es durchaus Möglichkeiten, Magnete zu beeinflussen. Standard-Methoden nutzen etwa eine elektromagnetische Spule, die durch...
Für den Anwender ist die zerstörungsfreie Werkstoffprüfung ein effektives Mittel, um schnell eine sichere Aussage über die Qualität seines Produktes bereits während des Fertigungsprozesses zu gewinnen. Die zerstörungsfreie Prüfung (ZfP) stellt insbesondere für die Herstellung von sicherheitsrelevanten Bauteilen, z. B. die B-Säule eines Autos, eine essentielle Qualitätssicherungsmaßnahme dar, da fehlerhafte Materialeigenschaften im Endprodukt schnell zum Versagen führen können. Mit der ZfP wird die Qualität eines Werkstücks getestet, ohne das Material selbst zu beschädigen oder die Oberfläche zu verändern.
Das Fraunhofer IZFP präsentiert auf der diesjährigen Blechexpo in Stuttgart ein Exponat zur »Zerstörungsfreien Prüfung pressgehärteter Karosseriebauteile mit...
Die Reinigung von Autoabgasen ist eines der bekanntesten katalytischen Verfahren. Doch nahezu die gesamte chemische Industrie basiert auf katalytischen Reaktionen. Das Katalysatordesign spielt daher eine Schlüsselrolle bei der Verbesserung vieler Prozesse. Ein internationales Team von Wissenschaftlern hat nun ein Konzept vorgestellt, das die geometrischen und die Adsorptionseigenschaften elegant miteinander in Beziehung setzt. Die Leistungsfähigkeit ihrer Methode zeigten sie am Beispiel eines neu entwickelten Platin-Katalysators für Brennstoffzellen.
Wasserstoff wäre ein idealer Energieträger: Überschüssige Windenergie könnte Wasser in seine Elemente zerlegen, mit dem Wasserstoff ließen sich höchst...
Nondestructive material testing (NDT) is a fast and effective way to analyze the quality of a product during the manufacturing process. Because defective materials can lead to malfunctioning finished products, NDT is an essential quality assurance measure, especially in the manufacture of safety-critical components such as automotive B-pillars. NDT examines the quality without damaging the component or modifying the surface of the material. At this year's Blechexpo trade fair in Stuttgart, Fraunhofer IZFP will have an exhibit that demonstrates the nondestructive testing of high-strength automotive body parts using 3MA. The measurement results are available in a matter of seconds.
To minimize vehicle weight and fuel consumption while providing the highest level of crash safety, automotive bodies are reinforced with elements made from...
Der Forschungsreaktor TRIGA an der Johannes Gutenberg-Universität Mainz (JGU) hat zwei Monate nach den Feierlichkeiten zu seinem 50-jährigen Bestehen einen...
09.10.2015 | Veranstaltungen
09.10.2015 | Veranstaltungen
08.10.2015 | Veranstaltungen
09.10.2015 | Messenachrichten
09.10.2015 | Messenachrichten
09.10.2015 | Innovative Produkte